AU2022275684A1 - Compositions for treatment of neurodegenerative conditions - Google Patents

Compositions for treatment of neurodegenerative conditions Download PDF

Info

Publication number
AU2022275684A1
AU2022275684A1 AU2022275684A AU2022275684A AU2022275684A1 AU 2022275684 A1 AU2022275684 A1 AU 2022275684A1 AU 2022275684 A AU2022275684 A AU 2022275684A AU 2022275684 A AU2022275684 A AU 2022275684A AU 2022275684 A1 AU2022275684 A1 AU 2022275684A1
Authority
AU
Australia
Prior art keywords
triol
ethynylandrost
ene
pharmaceutical composition
several embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022275684A
Other languages
English (en)
Inventor
Clarence Nathaniel Ahlem
Christopher L. Reading
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovie Inc
Original Assignee
Biovie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovie Inc filed Critical Biovie Inc
Publication of AU2022275684A1 publication Critical patent/AU2022275684A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022275684A 2021-05-18 2022-05-02 Compositions for treatment of neurodegenerative conditions Pending AU2022275684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189880P 2021-05-18 2021-05-18
US63/189,880 2021-05-18
PCT/US2022/027294 WO2022245532A1 (en) 2021-05-18 2022-05-02 Compositions for treatment of neurodegenerative conditions

Publications (1)

Publication Number Publication Date
AU2022275684A1 true AU2022275684A1 (en) 2023-11-16

Family

ID=84141848

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022275684A Pending AU2022275684A1 (en) 2021-05-18 2022-05-02 Compositions for treatment of neurodegenerative conditions

Country Status (7)

Country Link
US (1) US20240108636A1 (enExample)
EP (1) EP4341271A4 (enExample)
JP (1) JP2024519079A (enExample)
AU (1) AU2022275684A1 (enExample)
CA (1) CA3218191A1 (enExample)
MX (1) MX2023013616A (enExample)
WO (1) WO2022245532A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054452A1 (en) * 2022-09-06 2024-03-14 Biovie Inc. Methods for the treatment of mild cognitive impairment
WO2025155561A1 (en) * 2024-01-16 2025-07-24 Biovie Inc. Methods of treating long covid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015763A1 (en) * 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
CA2728889C (en) * 2008-04-03 2016-06-14 Harbor Biosciences, Inc. Solid state forms of a pharmaceutical

Also Published As

Publication number Publication date
WO2022245532A1 (en) 2022-11-24
EP4341271A1 (en) 2024-03-27
JP2024519079A (ja) 2024-05-08
US20240108636A1 (en) 2024-04-04
EP4341271A4 (en) 2025-04-30
CA3218191A1 (en) 2022-11-24
MX2023013616A (es) 2024-01-17

Similar Documents

Publication Publication Date Title
US12083107B2 (en) Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20240108636A1 (en) Compositions for treatment of neurodegenerative conditions
JP7557185B2 (ja) 免疫応答を調節するｇａｂａの能力の強化
JP2025510916A5 (enExample)
US12128012B2 (en) Ketamine treatment for amyotrophic lateral sclerosis
WO2012140504A1 (en) Therapeutic compounds
US20170029391A1 (en) Cyclohexenyl compounds, compositions comprising them and methods
WO2000066110A1 (en) Glycine cleavage system inhibitors as potential antipsychotics
CN101088498A (zh) 补骨脂酚类化合物的应用
KR101851603B1 (ko) 신경염증제어를 통한 파킨슨 질환 예방 또는 치료용 조성물
JP2014152175A (ja) カテプシンｋ抑制剤としてミリセチンの用途
CN111265523A (zh) 小檗碱、人参皂苷组合物在制备预防和/或治疗糖尿病伴发抑郁症的药物中的应用
CN108078984B (zh) 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用
KR20210045414A (ko) 병리학적 염증에 대한 새로운 의학적 치료
JP2011178702A (ja) 睡眠の改善剤
KR102346790B1 (ko) 콜히친과 메트포르민을 유효성분으로 하는 항비만 치료제
CN110893183A (zh) 银杏萜内酯在制备预防、缓解或治疗肌萎缩侧索硬化药物中的应用
TWI711449B (zh) 一種鼠尾草酸用於製備治療多巴胺失調疾病產生的異常不自主運動的醫藥組成物的用途
US11452704B2 (en) Prevention and treatment of muscle wasting with ketone supplementation
CN106138031A (zh) 桑辛素c在制备用于治疗糖尿病的药物中的应用
Hajim et al. Pharmacological Interaction Between Alpha-Lipoic Acid and Propofol-Induced General Anesthesia in Rats Model
CN107951872B (zh) 一种治疗糖尿病的口服药物组合物
CN120919102A (zh) 蛋氨酸在制备用于改善精神分裂症社交障碍的药物或组合物中的用途
KR20240070564A (ko) 알츠하이머병 예방 또는 치료용 약학적 조성물
CN103919776B (zh) 一种治疗关节炎的药物组合物